Logotype for SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group (SLS) Study result summary

Event summary combining transcript, slides, and related documents.

Logotype for SELLAS Life Sciences Group Inc

Study result summary

17 Nov, 2026

Trial design

  • Global, randomized, open-label Phase III REGAL enrolled 126 AML patients in CR2 or later/CRp2 or later after salvage therapy who could not undergo allogeneic transplant; patients were randomized 1:1 to GPS maintenance monotherapy or investigator-selected BAT.

  • Overall survival was the primary endpoint; GPS is an investigational, off-the-shelf WT1-targeting vaccine designed to stimulate CD4+ and CD8+ T-cell responses.

Efficacy results

  • REGAL met its primary endpoint, with a 41% reduction in risk of death for GPS versus BAT (HR 0.59; two-sided P=0.035); the primary analysis followed the prespecified 80-death threshold and statistical plan.

  • Median overall survival was 24.0 months with GPS versus 14.7 months with BAT.

Safety and control context

  • GPS was generally well tolerated, with no new safety signals; treatment-related events were predominantly grade 1/2 and included transient injection-site reactions.

  • BAT options included observation, hypomethylating agents, venetoclax and/or low-dose cytarabine; BAT median OS exceeded historical real-world benchmarks of ~8-10 months.

  • Treatment arms were balanced on prognostic stratification factors, and few patients proceeded to stem cell transplantation, equally distributed between arms.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from SELLAS Life Sciences Group